Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BCPC Stock Forecast 2026-2027
$177.52
Current Price
$5.75B
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BCPC Price Targets
+31.8%
To High Target of $234.00
+14.1%
To Median Target of $202.50
-8.2%
To Low Target of $163.00
BCPC Price Momentum
+1.1%
1 Week Change
+9.6%
1 Month Change
+13.1%
1 Year Change
+15.8%
Year-to-Date Change
-3.5%
From 52W High of $183.90
+27.6%
From 52W Low of $139.17
📊 TOP ANALYST CALLS
Did BCPC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Balchem is one of their latest high-conviction picks.
Latest BCPC Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, BCPC has a bullish consensus with a median price target of $202.50 (ranging from $163.00 to $234.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $177.52, the median forecast implies a 14.1% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BCPC Analyst Ratings
2
Buy
1
Hold
0
Sell
BCPC Price Target Range
Low
$163.00
Average
$202.50
High
$234.00
Current: $177.52
Latest BCPC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BCPC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $190.00 |
| Dec 5, 2025 | Rothschild & Co | Artem Chubarov | Neutral | Initiates | $162.00 |
| Oct 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $190.00 |
| Aug 4, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $189.00 |
| Apr 28, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $180.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $190.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $190.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $185.00 |
| May 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $170.00 |
| Feb 20, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 30, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $135.00 |
| Jul 31, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $165.00 |
| Jun 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $150.00 |
| Feb 27, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $140.00 |
| Nov 7, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $152.00 |
| Aug 22, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $164.00 |
| May 2, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $152.00 |
| Mar 8, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $155.00 |
| Feb 22, 2022 | Sidoti & Co. | Buy | Upgrade | $N/A | |
| Jan 10, 2022 | HC Wainwright & Co. | Buy | Maintains | $170.00 |
Balchem Corporation (BCPC) Competitors
The following stocks are similar to Balchem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Balchem Corporation (BCPC) Financial Data
Balchem Corporation has a market capitalization of $5.75B with a P/E ratio of 37.4x. The company generates $1.04B in trailing twelve-month revenue with a 14.9% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of +19.8% and return on equity of +12.9%.
Valuation Metrics
Market Cap
$5.75B
Enterprise Value
$5.80B
P/E Ratio
37.4x
PEG Ratio
2.0x
Price/Sales
5.5x
Growth & Margins
Revenue Growth (YoY)
+9.8%
Gross Margin
+35.6%
Operating Margin
+19.8%
Net Margin
+14.9%
EPS Growth
+16.8%
Financial Health
Cash/Price Ratio
+1.3%
Current Ratio
2.1x
Debt/Equity
14.4x
ROE
+12.9%
ROA
+8.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Balchem Corporation (BCPC) Business Model
About Balchem Corporation
What They Do
Develops specialty performance ingredients for various industries.
Business Model
The company operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. It generates revenue by providing human-grade nutrients, animal feed solutions, and performance gases and chemicals for diverse applications in food, pharmaceuticals, and industrial sectors.
Additional Information
Founded in 1967 and headquartered in New Jersey, Balchem Corporation emphasizes innovation in its offerings to enhance health and performance across multiple markets. It is a key player in the specialty chemicals industry, focusing on high-quality, technology-driven solutions.
Company Information
Sector
Basic Materials
Industry
Specialty Chemicals
Employees
1,364
CEO
Mr. Theodore Lee Harris
Country
United States
IPO Year
1986
Website
www.balchem.comBalchem Corporation (BCPC) Latest News & Analysis
Latest News
Quick Summary
Balchem reported nearly 10% YoY revenue growth in Q4, with all segments advancing. It has a 17-year record of double-digit dividend increases and trades at a 25% discount to fair value, with strong return potential.
Why It Matters
Balchem's strong Q4 performance and consistent dividend growth signal financial health. The stock's undervaluation suggests significant upside potential, appealing to value-focused investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Balchem Plant Nutrition has launched Metalosate® T.E.A.M., expanding its product line in chelated mineral plant nutrition.
Why It Matters
Balchem's launch of Metalosate® T.E.A.M. could enhance its product portfolio, potentially driving revenue growth and market share, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Balchem Stock Lands New $18 Million Investor as Firm Delivers Record $1 Billion in Sales
1 month ago
Quick Summary
Harvey Partners acquired 116,000 shares in Balchem Corporation in Q4, increasing their position value by $17.79 million.
Why It Matters
Harvey Partners' significant investment in Balchem Corporation signals confidence in its growth potential, likely influencing market perception and potentially driving share prices higher.
Source: The Motley Fool
Market Sentiment:
Positive
Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
1 month ago
Quick Summary
Balchem Corporation (NASDAQ: BCPC) will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026, focusing on health and nutrition markets.
Why It Matters
Balchem's participation in a prominent industry forum signals potential growth opportunities and market visibility, which can influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Balchem Corporation (NASDAQ: BCPC) will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026.
Why It Matters
Balchem's participation in the conference signals its commitment to industry engagement, potentially influencing investor confidence and market perception of its growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Balchem Corporation (BCPC) held its Q4 2025 earnings call, detailing financial performance and strategic outlook. Further specifics on revenue and projections were discussed in the transcript.
Why It Matters
Balchem's Q4 2025 earnings call provides insights into financial performance, growth prospects, and strategic direction, crucial for assessing investment opportunities and risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About BCPC Stock
What is Balchem Corporation's (BCPC) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Balchem Corporation (BCPC) has a median price target of $202.50. The highest price target is $234.00 and the lowest is $163.00.
Is BCPC stock a good investment in 2026?
According to current analyst ratings, BCPC has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $177.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BCPC stock?
Wall Street analysts predict BCPC stock could reach $202.50 in the next 12 months. This represents a 14.1% increase from the current price of $177.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Balchem Corporation's business model?
The company operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. It generates revenue by providing human-grade nutrients, animal feed solutions, and performance gases and chemicals for diverse applications in food, pharmaceuticals, and industrial sectors.
What is the highest forecasted price for BCPC Balchem Corporation?
The highest price target for BCPC is $234.00 from at , which represents a 31.8% increase from the current price of $177.52.
What is the lowest forecasted price for BCPC Balchem Corporation?
The lowest price target for BCPC is $163.00 from at , which represents a -8.2% decrease from the current price of $177.52.
What is the overall BCPC consensus from analysts for Balchem Corporation?
The overall analyst consensus for BCPC is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $202.50.
How accurate are BCPC stock price projections?
Stock price projections, including those for Balchem Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 3:03 PM UTC